World Health Organization Raises Alert Over Acute Lack of Weight-Loss Medications
Less than 10% of people eligible to benefit from weight-loss injections including Wegovy have access to them, states the WHO as it issues its first recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The latest guidelines acknowledges that excess weight is a long-term condition that can be managed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant obstacles to universal access to the injections that can help people shift significant weight, says the agency.
Weight-Loss Drug Shortage
Even in the current best projected scenario, the supply of these medications might only reach about 100 million people – under 10% of eligible patients, per the health organization.
The recommendation encourages governments and firms to increase availability, through approaches like licensing agreements.
The intellectual property rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is due to expire in multiple countries in 2026.
How Weight-Loss Injections Work
GLP-1 drugs mimick a natural hormone to delay gastric emptying, reduce hunger and boost the sense of being full so users consume fewer calories.
Individuals usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Studies indicates users may regain a significant portion after a year of discontinuing the treatment, as their normal hunger return.
To be overweight or obese raises your chance for developing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight concerns people in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
